Zimbabwe has declined a significant US health deal valued at 367 million US dollars (272 million pounds) over five years due to Washington's request for confidential data.
This move came to light following a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official spokesperson later clarified that the United States was requesting genetic material for research and commercial gain but was not willing to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for continued dialogue to find a deal suitable to both sides so the nation's critical HIV treatment initiative can proceed.
Broader Background
This rejection follows a similar case in neighbouring Kenya, where a court halted a similar health funding agreement after legal challenges were filed about the security of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had overseen aid for the US government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government agreements to boost openness and accountability.
According to statements, Sixteen nations in Africa have so far agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Declined Deal
The money for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that might be developed from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for medical research with no certainty that the final treatments would be available to our citizens if a future health crisis arise."
National Interest and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting structures previously set up through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This system is intended to ensure that when a country contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome ongoing dialogue with our US partners on how subsequent collaboration might be structured in a manner that honours the sovereignty and dignity of each country."
Health Experts Response
A leading public health body stated it acknowledged the government's concerns, but urged that negotiations must proceed since a large portion of the country's HIV programmes depended on foreign aid.
"If specific concerns arise, including those relating to data governance or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," the group commented.
The halted deal highlights the complex debate between receiving much-needed international aid and protecting local interests in an increasingly data-driven world.